Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-224 in Advanced Solid Tumors
NCT05219578Phase 2Terminated
- Sponsor
- Rubius Therapeutics
- Start
- Jan 2022
- Primary completion
- Nov 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of RTX-224 in non-small cell lung cancer (NSCLC), cutaneous melanoma (CM), head and neck squamous cell carcinoma (HNSCC) and 2 more (2 arms), sponsored by Rubius Therapeutics. Primary endpoints: Safety Assessment by rate of Adverse Events up to 30 months and Dose limiting toxicities up to 30 months. Started Jan 2022; status: terminated.
02
Drugs
RTX-224
03
Conditions
non-small cell lung cancer (NSCLC)cutaneous melanoma (CM)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05219578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219578.